MENU
Go to the list of all blogs
Anna G's Avatar
published in Blogs
May 21, 2023

Analyzing the Downturn: Unveiling the Story Behind Hims & Hers Health's (HIMS) -12.69% Monthly Descent

Unlocking the Power of Artificial Intelligence to Make Trading Decisions with Tickeron's AI Robots.

In the competitive realm of healthcare and personal care, Hims & Hers Health (HIMS) faced a challenging month, witnessing a significant downturn of -12.69% and closing at $9.77 per share. This blog post aims to unravel the story behind Hims & Hers Health's notable setback, shedding light on the broader trends within the Household/Personal Care Industry. Join us as we dive into the analysis, examining the factors that contributed to the company's descent and exploring the market landscape that influenced its performance.

Understanding the Household/Personal Care Industry: To gain insights into Hims & Hers Health's performance, it is essential to understand the dynamics of the Household/Personal Care Industry. Our analysis of 95 stocks in this sector reveals that 47.37% exhibited an Uptrend, while 52.63% experienced a Downtrend. This industry overview sets the stage for comprehending the specific challenges and opportunities faced by Hims & Hers Health.

Factors Impacting Hims & Hers Health's Descent: Multiple factors may have influenced Hims & Hers Health's -12.69% monthly decline. Market conditions, competitive pressures, regulatory changes, or internal operational factors could have played a role in the company's setback. By examining these factors in detail, we can gain valuable insights into the circumstances that impacted Hims & Hers Health's performance.

Navigating the Landscape of Household/Personal Care: As investors evaluate the impact of Hims & Hers Health's descent, it becomes crucial to navigate the Household/Personal Care Industry with a discerning eye. Understanding the current market outlook, identifying potential opportunities, and assessing the risks associated with the sector are vital considerations for informed decision-making. This blog post provides valuable insights and strategies to help investors navigate the ever-evolving landscape of the Household/Personal Care Industry amidst Hims & Hers Health's downturn.

Hims & Hers Health's -12.69% monthly descent serves as a reminder of the volatility and challenges inherent in the Household/Personal Care Industry. By analyzing the broader market trends and uncovering the factors that influenced Hims & Hers Health's performance, investors can gain a comprehensive understanding of the landscape. In an industry that continues to evolve rapidly, staying informed, adapting to market conditions, and identifying potential opportunities while managing risks are crucial for investors seeking success in the Household/Personal Care sector.

Related Ticker: HIMS

HIMS in +0.48% Uptrend, advancing for three consecutive days on October 09, 2025

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where HIMS advanced for three days, in of 292 cases, the price rose further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

HIMS moved above its 50-day moving average on September 18, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for HIMS crossed bullishly above the 50-day moving average on September 18, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 293 cases where HIMS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for HIMS moved out of overbought territory on September 15, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 42 similar instances where the indicator moved out of overbought territory. In of the 42 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 60 cases where HIMS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The Momentum Indicator moved below the 0 level on October 10, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on HIMS as a result. In of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for HIMS turned negative on October 10, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where HIMS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

HIMS broke above its upper Bollinger Band on September 11, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. HIMS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock slightly better than average.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (21.978) is normal, around the industry mean (17.612). P/E Ratio (69.278) is within average values for comparable stocks, (72.701). Projected Growth (PEG Ratio) (3.898) is also within normal values, averaging (1.982). HIMS has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.031). P/S Ratio (6.698) is also within normal values, averaging (47.252).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

Notable companies

The most notable companies in this group are ZOETIS (NYSE:ZTS), Teva Pharmaceutical Industries Limited (NYSE:TEVA), Elanco Animal Health (NYSE:ELAN), Bausch Health Companies (NYSE:BHC), Tilray Brands (NASDAQ:TLRY), BioCryst Pharmaceuticals (NASDAQ:BCRX), Avadel Pharmaceuticals plc (NASDAQ:AVDL), Canopy Growth Corp (NASDAQ:CGC), Aurora Cannabis (NASDAQ:ACB), Journey Medical Corp (NASDAQ:DERM).

Industry description

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

Market Cap

The average market capitalization across the Pharmaceuticals: Generic Industry is 3.94B. The market cap for tickers in the group ranges from 4.24K to 63.66B. AGN holds the highest valuation in this group at 63.66B. The lowest valued company is CANQF at 4.24K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Generic Industry was -2%. For the same Industry, the average monthly price growth was 3%, and the average quarterly price growth was 53%. ORXOY experienced the highest price growth at 45%, while OASMY experienced the biggest fall at -50%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Generic Industry was -23%. For the same stocks of the Industry, the average monthly volume growth was -10% and the average quarterly volume growth was 17%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 52
P/E Growth Rating: 65
Price Growth Rating: 54
SMR Rating: 82
Profit Risk Rating: 90
Seasonality Score: -1 (-100 ... +100)
View a ticker or compare two or three
HIMS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. HIMS showed earnings on August 04, 2025. You can read more about the earnings report here.
A.I. Advisor
published General Information

General Information

a company, which is involved in real estate investment trusts

Industry PharmaceuticalsGeneric

Profile
Fundamentals
Details
Industry
N/A
Address
2269 Chestnut Street
Phone
+1 415 851-0195
Employees
658
Web
https://www.forhims.com
Interact to see
Advertisement
Paper wallets are extremely useful tools – beyond being one of the most popular and secure cold storage methods, they make it simple to transfer coins between owners.You can access the funds on your paper wallet by “sweeping” (or importing) them to either a live wallet (like Trezor or Exodus) or an exchange service (like Coinbase). Most services allow you to import them directly from your wallet’s private key, but there are two key exceptions.
Learn the 27 essential intraday trading rules that every manual trader should master—and discover how Tickeron’s AI platform applies them automatically for consistent, emotion-free execution and smarter, real-time decision-making.
#investment#trading
A $2 trillion sell-off has investors asking: is 2025 the next dot-com crash or a replay of the 2008 recession? This deep dive compares both scenarios, outlines warning signs, and reveals how AI-powered trading strategies can help navigate rising volatility.
#trading#investment
New to trading? Discover 21 powerful lessons every beginner must learn—and see how Tickeron’s AI Double Agent strategies apply them in real time. From mastering risk to managing emotions, this guide helps you trade smarter, safer, and more confidently.
#investment#trading
From the railroads of the 1920s to the AI giants of 2025, market history shows that extreme concentration often precedes massive bubbles and crashes. This article explores five key turning points and how Tickeron’s AI helps traders navigate today’s bubble-prone landscape.
#investment#trading
U.S. tariff tensions rocked markets this week, sending tech stocks into retreat and safe-haven assets like gold and the yen soaring. As investors brace for major earnings and global policy shifts, volatility remains high across equities, currencies, and commodities.
#investment#trading
Tesla’s Q1 2025 earnings could surprise investors as the EV giant looks to rebound from last quarter’s miss. With lowered expectations and increased volatility, Tickeron’s AI-powered strategy helps traders navigate both upside potential and downside risk.
#investment#trading
Gold is on a historic run—up 29% YTD with record-breaking inflows and growing macro tailwinds. Discover why smart investors are eyeing gold, silver, and miners for opportunity, and how AI trading tools are unlocking new ways to profit from the 2025 gold rush.
#investment#trading
Wall Street expects strong profit growth from the Magnificent Seven tech giants in 2025. Discover how to trade Apple, Microsoft, Amazon, Nvidia, Tesla, Meta, and Alphabet using AI-powered Double Agent strategies and smart hedging with inverse ETFs like QID.
On May 2, 2025, a diverse group of companies across energy, financial services, basic materials, consumer discretionary, and healthcare will release their Q1 2025 earnings.
In April 2025, five tech giants—NVIDIA, Tesla, Meta, Palantir, and Amazon—each surged over 40%, driven by AI breakthroughs, strong earnings, and market momentum. Discover what fueled the rally and how Tickeron’s AI trading bots helped investors outperform even these star stocks.
#investment
Markets ended April with mixed signals—gold slid on trade optimism, Big Tech lifted the Nasdaq, and Bitcoin steadied near $94K. With U.S. GDP contracting and job growth beating forecasts, investors brace for more volatility amid tariffs and central bank moves.
As Warren Buffett announces his retirement, investors turn to his trusted Buffett Indicator—a ratio of market cap to GDP—as a key gauge of market valuation.
#investment
Markets move in repeating cycles—Accumulation, Uptrend, Distribution, and Downtrend. Learn how to recognize each phase and deploy Tickeron’s AI-powered Double Agent strategy to adapt, protect capital, and profit in any market condition.
#trading
Discover how confirmation trading techniques—like moving average crossovers and volume-backed breakouts—can improve accuracy and reduce false signals. Learn how Tickeron’s AI automates these strategies for smarter, faster, and more disciplined trading.
#trading
Hedge funds are ramping up bearish bets on small-cap stocks, with Russell 2000 short interest hitting new highs. As macro headwinds mount and technical support teeters, Tickeron’s AI Double Agents step in to navigate the looming sell-off with precision.
#investment#trading#artificial_intelligence
SPY’s Momentum Indicator turned bullish on April 25, 2025, signaling a potential trend shift with a 90% historical success rate. This article explores how economic scarcity, technical signals, and AI-driven tools like Tickeron’s A.I.dvisor shape investor decisions in volatile markets.
#trading
On May 7, 2025, NVIDIA gained 3.1% on bullish AI momentum and strong data center demand, while Alphabet plunged over 7% amid regulatory fears and growing AI competition—highlighting the tech sector's diverging fortunes in a volatile market.
#investment
A volatile week in financial markets saw the S&P 500 pull back after a record streak, gold surge nearly 5% on Fed jitters, and Bitcoin soar past $104K on trade deal hopes—highlighting the growing impact of policy decisions, earnings, and geopolitical sentiment on asset prices.
ickeron’s AI-powered prediction that Bitcoin would reach $109,000 is nearing reality, as BTC climbs to $103,000. This article explores the accuracy of the forecast, the market forces behind the rally, and how traders can leverage AI tools like Double Agents to stay ahead.
#trading#investment